Not recruitingISRCTN11177045
IVIG and rituximab in antibody-associated psychosis - SINAPPS2
Research studyAges 16–70United KingdomSchizophrenia
Understand this study
Who could participate?
Listed age limits: 16 years to 70 years.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2017
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
- Sponsor type
- University
- Study type
- Other
- Intervention type
- Other / unclear
- Locations
- United Kingdom
- Age range
- From 16 Years to 70 Years
- Official registry ID
- ISRCTN11177045
- Official title
Show the full official title
A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge · Exeter · Glasgow
6 more locations
- Liverpool
- London
- Manchester
- Nottingham
- Oxford
- Sheffield
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, a university.
Who can participate?
Listed age limits: 16 years to 70 years.
Is this study still recruiting?
The registry lists this study as not recruiting.
